]>
IRCT20191016045131N1 IRCT 2019-12-30 Yazd University of Medical Sciences The effect of oral L-carnitine supplementation on polycystic ovary syndrome Comparison of the effect of oral L-carnitine and placebo supplementation on anthropometric indices, lipid status, insulin and hormone resistance indices in obese / overweight women suffering from polycystic ovary syndrome 2019-10-21 anticipated 62 Complete https://irct.ir/trial/43141 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random allocation tables, Blinding description: Blinding the researcher and participants. For this purpose the tablets were initially packaged in two packages A and B.The nature of the tablets will remain hidden from the participants and researchers until after the study. 3 Polycystic Ovarian Syndrome. Intervention 1: Control group: receiving placebo containing non-active substance for 12 weeks. Intervention 2: Intervention group: Oral administration of L-carnitine supplement 1000 mg daily for 12 weeks. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is No more information
public Fatemeh Pakravanfar
Alem square
Yazd Iran (Islamic Republic of) 8715113514 +98 31 5557 3812 fatemeh.p1993@yahoo.com Yazd University of Medical Sciences scientific Fatemeh Pakravanfar
Alem square
yazd Iran (Islamic Republic of) 8715113514 +98 31 5557 3812 fatemeh.p1993@yahoo.com Yazd University of Medical Sciences Iran (Islamic Republic of) 18-45 years old women referred to Yazd Diabetes Center Polycystic ovary syndrome based on Rotterdam diagnostic criteria Body Mass Index 25 and over interested in participation in the study Taking usual treatment of PCOS 18 years 45 years Female Smoking Suffering from diabetes or thyroid disease Having a special diet for the past three months Weight-loss medication, hormone or ovulation stimulant use E28.2 Polycystic Ovarian Syndrome Placebo Treatment - Drugs Control group: receiving placebo containing non-active substance for 12 weeks Intervention group: Oral administration of L-carnitine supplement 1000 mg daily for 12 weeks Insulin. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: Insulin Kit. Fasting blood sugar. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: Blood test. Sex hormone-binding globulin. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: kit. Triglyceride. Timepoint: At the beginning and at the end of the study (120 days after). Method of measurement: Blood test. Cholesterol. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: Blood test. HDL. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: Blood test. LDL. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: Blood test. HOMA IR. Timepoint: At the beginning and at the end of the study (120 days later). Method of measurement: By formula using fasting glucose and insulin. Yazd University of Medical Sciences Approved 2018-05-22 Ethics committee of Yazd University of Medical Sciences Central Building of Shahid Sadoughi University of Medical Sciences, Bahonar Square Yazd Yazd Iran (Islamic Republic of)